X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Ingersoll Rand - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs INGERSOLL RAND - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

INGERSOLL RAND 
   Change

Ingersoll Rand is a global diversified industrial company, engaged in the business of providing solutions for infrastructure development, industrial solutions, residential solutions and security technologies. Ingersoll-Rand manufactures a wide range ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES INGERSOLL RAND INDOCO REMEDIES/
INGERSOLL RAND
 
P/E (TTM) x 23.0 32.3 71.4% View Chart
P/BV x 2.7 2.4 116.5% View Chart
Dividend Yield % 0.8 0.8 108.9%  

Financials

 INDOCO REMEDIES   INGERSOLL RAND
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
INGERSOLL RAND
Mar-17
INDOCO REMEDIES/
INGERSOLL RAND
5-Yr Chart
Click to enlarge
High Rs360789 45.7%   
Low Rs249625 39.9%   
Sales per share (Unadj.) Rs119.0214.5 55.5%  
Earnings per share (Unadj.) Rs8.424.5 34.2%  
Cash flow per share (Unadj.) Rs15.228.2 54.0%  
Dividends per share (Unadj.) Rs1.606.00 26.7%  
Dividend yield (eoy) %0.50.8 61.9%  
Book value per share (Unadj.) Rs70.7336.3 21.0%  
Shares outstanding (eoy) m92.1531.57 291.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.3 77.7%   
Avg P/E ratio x36.428.9 126.2%  
P/CF ratio (eoy) x20.025.1 79.9%  
Price / Book Value ratio x4.32.1 205.0%  
Dividend payout %19.124.5 78.0%   
Avg Mkt Cap Rs m28,08322,315 125.8%   
No. of employees `0006.00.7 877.3%   
Total wages/salary Rs m2,167937 231.1%   
Avg. sales/employee Rs Th1,817.09,842.7 18.5%   
Avg. wages/employee Rs Th359.01,362.5 26.3%   
Avg. net profit/employee Rs Th127.71,123.2 11.4%   
INCOME DATA
Net Sales Rs m10,9686,772 162.0%  
Other income Rs m40588 6.8%   
Total revenues Rs m11,0077,360 149.6%   
Gross profit Rs m1,565682 229.4%  
Depreciation Rs m633118 536.3%   
Interest Rs m628 786.1%   
Profit before tax Rs m9091,144 79.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139371 37.4%   
Profit after tax Rs m771773 99.7%  
Gross profit margin %14.310.1 141.6%  
Effective tax rate %15.332.4 47.0%   
Net profit margin %7.011.4 61.6%  
BALANCE SHEET DATA
Current assets Rs m5,7259,125 62.7%   
Current liabilities Rs m5,4541,346 405.2%   
Net working cap to sales %2.5114.9 2.1%  
Current ratio x1.06.8 15.5%  
Inventory Days Days6247 132.1%  
Debtors Days Days7250 142.4%  
Net fixed assets Rs m5,3071,280 414.5%   
Share capital Rs m184316 58.4%   
"Free" reserves Rs m6,33110,300 61.5%   
Net worth Rs m6,51610,616 61.4%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97012,057 99.3%  
Interest coverage x15.6145.8 10.7%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.6 163.1%   
Return on assets %7.06.5 107.5%  
Return on equity %11.87.3 162.5%  
Return on capital %12.410.9 114.2%  
Exports to sales %026.5 0.0%   
Imports to sales %020.1 0.0%   
Exports (fob) Rs mNA1,792 0.0%   
Imports (cif) Rs mNA1,363 0.0%   
Fx inflow Rs m4,5071,792 251.5%   
Fx outflow Rs m1,1411,603 71.2%   
Net fx Rs m3,366188 1,787.0%   
CASH FLOW
From Operations Rs m8861,215 73.0%  
From Investments Rs m-1,7061,407 -121.2%  
From Financial Activity Rs m1,316-231 -569.8%  
Net Cashflow Rs m4972,391 20.8%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 74.0 -  
Indian inst/Mut Fund % 12.5 7.2 173.6%  
FIIs % 6.0 0.5 1,200.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 18.3 122.4%  
Shareholders   12,805 19,522 65.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   GEOJIT BNP PARIBAS  KOTHARI PRODUCTS  NESCO LIMITED  IIFL HOLDINGS  GREENPLY IND  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 21, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS